ANDROGEL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Androgel, and what generic alternatives are available?
Androgel is a drug marketed by Besins Hlthcare and is included in two NDAs. There are eight patents protecting this drug.
This drug has forty-five patent family members in twenty-nine countries.
The generic ingredient in ANDROGEL is testosterone. There are sixty-nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Androgel
A generic version of ANDROGEL was approved as testosterone by ACTAVIS LABS UT INC on January 27th, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ANDROGEL?
- What are the global sales for ANDROGEL?
- What is Average Wholesale Price for ANDROGEL?
Summary for ANDROGEL
International Patents: | 45 |
US Patents: | 8 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Clinical Trials: | 55 |
Patent Applications: | 4,284 |
Drug Prices: | Drug price information for ANDROGEL |
Drug Sales Revenues: | Drug sales revenues for ANDROGEL |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ANDROGEL |
What excipients (inactive ingredients) are in ANDROGEL? | ANDROGEL excipients list |
DailyMed Link: | ANDROGEL at DailyMed |
Recent Clinical Trials for ANDROGEL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
VA Office of Research and Development | Phase 2 |
University Medical Center Groningen | N/A |
National Heart, Lung, and Blood Institute (NHLBI) | Phase 4 |
Pharmacology for ANDROGEL
Drug Class | Androgen |
Mechanism of Action | Androgen Receptor Agonists |
US Patents and Regulatory Information for ANDROGEL
ANDROGEL is protected by eight US patents.
Patents protecting ANDROGEL
Testosterone gel and method of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Testosterone gel and method of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
Testosterone gel and method of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
Testosterone gel and method of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Testosterone gel and method of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Testosterone gel and method of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
Testosterone gel and method of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Testosterone gel and method of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Besins Hlthcare | ANDROGEL | testosterone | GEL, METERED;TRANSDERMAL | 022309-001 | Apr 29, 2011 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Besins Hlthcare | ANDROGEL | testosterone | GEL;TRANSDERMAL | 022309-003 | Sep 7, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Besins Hlthcare | ANDROGEL | testosterone | GEL;TRANSDERMAL | 022309-003 | Sep 7, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Besins Hlthcare | ANDROGEL | testosterone | GEL, METERED;TRANSDERMAL | 022309-001 | Apr 29, 2011 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Besins Hlthcare | ANDROGEL | testosterone | GEL, METERED;TRANSDERMAL | 022309-001 | Apr 29, 2011 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Besins Hlthcare | ANDROGEL | testosterone | GEL;TRANSDERMAL | 022309-002 | Sep 7, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Besins Hlthcare | ANDROGEL | testosterone | GEL;TRANSDERMAL | 022309-003 | Sep 7, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ANDROGEL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Besins Hlthcare | ANDROGEL | testosterone | GEL, METERED;TRANSDERMAL | 021015-003 | Sep 26, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Besins Hlthcare | ANDROGEL | testosterone | GEL;TRANSDERMAL | 022309-003 | Sep 7, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Besins Hlthcare | ANDROGEL | testosterone | GEL;TRANSDERMAL | 022309-003 | Sep 7, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Besins Hlthcare | ANDROGEL | testosterone | GEL, METERED;TRANSDERMAL | 022309-001 | Apr 29, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Besins Hlthcare | ANDROGEL | testosterone | GEL;TRANSDERMAL | 021015-001 | Feb 28, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Besins Hlthcare | ANDROGEL | testosterone | GEL;TRANSDERMAL | 022309-003 | Sep 7, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Besins Hlthcare | ANDROGEL | testosterone | GEL, METERED;TRANSDERMAL | 021015-003 | Sep 26, 2003 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ANDROGEL
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Warner Chilcott UK Ltd. | Intrinsa | testosterone | EMEA/H/C/000634 Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy. |
Withdrawn | no | no | no | 2006-07-28 | |
Warner Chilcott Deutschland GmbH | Livensa | testosterone | EMEA/H/C/000630 Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy. |
Withdrawn | no | no | no | 2006-07-28 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ANDROGEL
See the table below for patents covering ANDROGEL around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Africa | 200407403 | Androgen pharmaceutical composition and method for treating depression | ⤷ Sign Up |
South Africa | 200301686 | Method of increasing testosterone and related steroid concentrations in women. | ⤷ Sign Up |
Ukraine | 87627 | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ В ВИДЕ ТЕСТОСТЕРОНОВОГО ГЕЛЯ И ЕЕ ИСПОЛЬЗОВАНИЕ ПРИ ЛЕЧЕНИИ ГИПОГОНАДИЗМА У МУЖЧИН;ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ У ВИГЛЯДІ ТЕСТОСТЕРОНОВОГО ГЕЛЮ ТА ЙОГО ЗАСТОСУВАННЯ ПРИ ЛІКУВАННІ ГІПОГОНАДИЗМУ В ЧОЛОВІКІВ (TESTOSTERONE GEL FORMULATION AND ITS USE FOR TREATING HYPOGONADISM IN MAN) | ⤷ Sign Up |
Eurasian Patent Organization | 009815 | УПАКОВКА С ДОЗИРОВАННОЙ ФОРМОЙ ТЕСТОСТЕРОНОВОГО ГЕЛЯ ДЛЯ ЛЕЧЕНИЯ ГИПОГОНАДИЗМА И СПОСОБ ЕЁ ПОЛУЧЕНИЯ (TESTOSTERONE GEL IN UNIT DOSE PACKET FOR TREATING HYPOGONADISM AND METHOD FOR PREPARING THEREOF) | ⤷ Sign Up |
South Korea | 20050074896 | ⤷ Sign Up | |
Norway | 20082170 | ⤷ Sign Up | |
Norway | 20200014 | Forbedret testosterongel og fremgangsmåte til anvendelse | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |